Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

(2012) C M M Prado et al.   BRITISH JOURNAL OF CANCER

Dual Specificity Phosphatase 4 Mediates Cardiomyopathy Caused by Lamin A/C (LMNA) Gene Mutation

(2012) Jason C. Choi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Altered mitogen-activated protein kinase signaling in dystrophic (mdx) muscle

(2012) Gayle M. Smythe et al.   MUSCLE & NERVE

Treatment with selumetinib preserves cardiac function and improves survival in cardiomyopathy caused by mutation in the lamin A/C gene

(2011) A. Muchir et al.   CARDIOVASCULAR RESEARCH

LMNA cardiomyopathy: cell biology and genetics meet clinical medicine

(2011) J. T. Lu et al.   Disease Models & Mechanisms

Novel mitogen-activated protein kinase kinase inhibitors

(2011) Mark S Chapman et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

MEK inhibitors: a patent review 2008 – 2010

(2011) John I Trujillo   EXPERT OPINION ON THERAPEUTIC PATENTS

Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A

(2011) A. Kumar et al.   HUMAN MOLECULAR GENETICS

Role of TGF-β signaling in inherited and acquired myopathies

(2011) Tyesha N Burks et al.   Skeletal Muscle

Mitogen-Activated Protein Kinase Inhibitors Improve Heart Function and Prevent Fibrosis in Cardiomyopathy Caused by Mutation in Lamin A/C Gene

(2010) Wei Wu et al.   CIRCULATION

The Nuclear Envelope as a Signaling Node in Development and Disease

(2009) William T. Dauer et al.   DEVELOPMENTAL CELL

Laminopathies and the long strange trip from basic cell biology to therapy

(2009) Howard J. Worman et al.   JOURNAL OF CLINICAL INVESTIGATION